Gilead Sciences GILD · USD
Health Care · Biotechnology · US listing · 🇺🇸 United States
S&P 500Nasdaq-100
169.32
+1.46%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gilead Sciences
From its filings with the US Securities and Exchange Commission
Gilead Sciences is based in Foster City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GILD. It is a member of the S&P 500 and Nasdaq-100. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $29.44bn and net income of $8.51bn. At that date it held total assets of $59.02bn and shareholders' equity of $22.70bn. By business, Product sales brought in 98.2% of revenue, followed by Royalty, contract and other revenues at 1.8%. By region, U.S. accounted for 70.9%, followed by Europe at 17.2% and Rest of World at 11.9%.
Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as “Gilead,” the “company,” “we,” “our” or “us”) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California.
We have transformed care for people around the world by discovering, developing and delivering innovative medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Our innovative medicines represent advancements by offering first-in-class therapies, greater efficacy, enhanced modes of delivery, more convenient treatment and prevention regimens, improved resistance profiles and reduced side effects.
(1) This indication is approved under accelerated approval by FDA, and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Jan 1992
- Employees
- 17,000
- Website
- gilead.com ↗
- Head office
- 333 LAKESIDE DR, FOSTER CITY, CA, 94404
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Daniel O'DayChairman of the Board, Chief Executive Officer, since 2019$23.7m
- Mr. Andrew DickinsonChief Financial Officer$8.1m
- Ms. Keeley WettanExecutive Vice President, General Counsel, Legal & Compliance
- Ms. Erin BurkhartSenior Vice President, Principal Accounting Officer, Controller
- Dr. Dietmar BergerChief Medical Officer
- Ms. Johanna MercierChief Commercial Officer$8.6m
- Mr. Anthony WeltersLead Independent Director$474,263
- Dr. Jacqueline BartonIndependent Director$429,960
- Dr. Jeffrey BluestoneIndependent Director$409,960
- Dr. Sandra HorningIndependent Director$429,960
- Ms. Kelly KramerIndependent Director$434,960
- Dr. Ted LoveIndependent Director$475,257
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 88
- Environment
- 86
- Social
- 91
- Governance
- 87
- Direct emissions (scope 1)
- 56,096 t
- Energy emissions (scope 2)
- 53,778 t
- Value chain emissions (scope 3)
- 1,121,798 t
- Women in the workforce
- 53%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Gilead Sciences Inc has several notable strengths that contribute to its success in the pharmaceutical industry. Firstly, the company possesses a strong portfolio of innovative and high-quality drugs, particularly in the fields of antiviral and antifungal medications. These products have gained considerable recognition and have established Gilead Sciences as a trusted name in the industry.
- Another strength of Gilead Sciences Inc lies in its robust research and development capabilities. The company invests heavily in scientific advancements and clinical trials, allowing them to discover breakthrough treatments and maintain a competitive edge. This commitment to innovation has resulted in numerous successful drug launches and a strong pipeline for future growth.
Weaknesses
- Despite its strengths, Gilead Sciences Inc faces certain weaknesses that it needs to address. One aspect is its heavy reliance on a limited number of key products for a significant portion of its revenue. This creates a vulnerability to fluctuations in demand or potential patent expirations, which could impact the company's financial performance.
- Additionally, Gilead Sciences has faced criticism for the high cost of some of its medications, particularly those treating chronic conditions such as HIV. The pricing strategy has led to public scrutiny and potential challenges in terms of affordability and accessibility for patients. Addressing these concerns could help improve the company's reputation and customer relationships.
Opportunities
- Gilead Sciences Inc has several opportunities to further expand its market presence and generate growth. One major opportunity lies in the emerging markets, where there is a growing demand for pharmaceutical products. By tapping into these regions and adapting their business strategies accordingly, Gilead Sciences can extend its reach and increase its market share.
- The company also has the opportunity to explore potential partnerships or collaborations with other pharmaceutical firms or research institutions. Such alliances can lead to knowledge sharing, joint development of new drugs, and shared resources, ultimately enhancing Gilead Sciences' product offerings and competitive advantage.
Threats
- Gilead Sciences Inc faces certain threats that could hinder its growth and profitability. One prominent threat is the intense competition within the pharmaceutical industry. Rival companies continuously strive to innovate and launch similar products, thereby reducing Gilead Sciences' market share and pricing power.
- Moreover, regulatory and legal challenges present additional threats. Strict regulations, patent disputes, and changes in healthcare policies can impact the company's ability to market and distribute its drugs effectively. To mitigate these threats, Gilead Sciences must continually adapt and comply with evolving regulations while safeguarding its intellectual property rights.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.